Test data protection TRIPS requirements & TRIPS-plus provisions Carlos Correa.

Slides:



Advertisements
Similar presentations
Impact of JUSFTA on affordability and availability of medicines from perspective of local generic manufacturers Towards equitable and affordable medicine.
Advertisements

JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
WTO/WHO Workshop on Differential Pricing-8-11 April 2001 By Carlos M. Correa University of Buenos Aires.
Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management.
The TRIPS Agreement and Public Health
Pharma Workshop IV Patent Linkage in the USA Lawrence T. Welch Eli Lilly and Company.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
Access to medicines – Barriers relating to intellectual property rights and data exclusivity Julian Cockbain & Sigrid Sterckx Yale conference Human rights.
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
Canada’s Paragraph 6 Legislation: What next? Rachel Kiddell-Monroe Coordinator for Access to Essential Medicines Campaign, MSF Canada.
1 Review of Art 39.3 TRIPS – interpretation and controversy Sanya Smith Third World Network 25 August 2006 Bangkok.
Biopharmaceutical Regulatory Requirements 1. Marketing Authorization for Chemical Entities MoH Federal Commission for the Protection against Health Risks.
The Protection of Data Submitted to Drug registration Authorities
1 Licensing Agreements and the Protection of Intellectual Property Chapter 17 © 2005 Thomson/West Legal Studies In Business.
© 2009 Pharmaceutical Law Group PC Market Exclusivity Paradigm Gregory J. Glover, MD, JD Pharmaceutical Law Group
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON,
Generic Substitution Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
International Max Planck Research School for Competition and Innovation WIPO – Owais Hassan Shaikh IMPRS-CI 2010 Data Exclusivity in Free Trade.
1 International Legal Framework for the Protection of Geographical Indications Warsaw, 26 April 2006 Denis Croze Acting Director Advisor Economic Development.
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
S UB - REGIONAL W ORKSHOP ON THE P ROTECTION OF I NVENTION IN P HARMACEUTICAL S ECTOR, P ATENT, U NDISCLOSED I NFORMATION AND H EALTH P OLICIES Organized.
Export University in association with InfoAmericas Exporting 201 – Focus on Latin America Presented by: José I. Rojas May 25, 2007 Intellectual Property.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
CAPACITY BUILDING TRAINING PROGRAMME ON IPR, WTO RELATED ISSUES AND PATENT WRITING April 28-May 2, 2008 Session 10 GIs negotiations in the WTO and other.
EPA Negotiations: Intellectual Property and Sustainable Development for ECOWAS Countries By Catherine Grant Director: Trade Policy Business Unity South.
Biotech Inventions in Latin America Argentina Ignacio Sánchez Echagüe Marval, O’Farrell & Mairal.
International Max Planck Research School for Competition and Innovation WIPO – Owais Hassan Shaikh IMPRS-CI 2010 Data Exclusivity Provisions.
Data exclusivity, patents and registration of medicines Karin Timmermans TWN Regional Workshop Kuala Lumpur on bilateral trade agreements Aug
Intellectual Property Protection of Data for Registration of Medicines James Love, CPTech International Conference on IPRs and Public Health FICCI and.
Data Exclusivity and Access to Medicines – Empirical Evidence Hearing European Parliament: EU-India Free Trade Agreement: What Future for Patients in Developing.
Intellectual Property Rights in the WTO CARSTEN FINK The WTO and the Doha Development Agenda Washington, DC, April 26, 2005.
EXCLUSIVE MARKETING RIGHTS & MAIL-BOX APPLICATIONS BY Manish Kumar Prusty T. Harish.
Ten Years of the Doha Declaration: The State of Implementation Geneva 14 November
Session 6 : An Introduction to the TRIPS Agreement UPOV, 1978 and 1991 and WIPO- Administered Treaties.
Chinese Foreign Trade Law Jiaxiang Hu Professor of Law, School of Law, SJTU.
World Trade Organization (WTO) accession and implications for public health Sanya Reid Smith Third World Network Kiev 22 September
The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.
Trade Related Aspects of Intellectual Property Rights FAO Regional Workshop on WTO Accession Damascus, October 2008 Hamish Smith Agriculture and.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
UNCTAD/CD-TFT 1 Basic Features of the Multilateral Systems of Patents and Regulatory Test Data Development Dimensions of Intellectual Property Rights Hanoi.
Protection of IPRs in Accession to WTO. Accession negotiations Multilateral (rules) Bilateral (individual members’ demands)
Data Protection in compliance with Article 39 of the TRIPS Agreement Draft Amendment to the Drugs Act 1976 Humaira Mufti WIPO National Seminar on Flexibilities.
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
Agreement on TRIPS TRIPS Agreement  When the WTO was established, it led to 18 specific agreements to which all members need to adhere. Members necessarily.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
WTO and the TRIPS Agreement Wolf R. MEIER-EWERT WTO Secretariat A Business-oriented overview of Intellectual Property for Law Students WIPO, Geneva 20.
Copyright © 2010 by K&L Gates LLP. All rights reserved. The Biosimilars Act—A Basic Introduction Michael H. Hinckle K&L Gates Research Triangle Park, NC.
Access to medicines Elizabeth Holzer, Legal Policy Advisor A global and local - legal and health systems issues.
Initiatives Drive Pediatric Drug Development January 30, 2002.
1 Overview of Data Protection, Data Exclusivity and Patent/Registration Linkage Prof. Brook K. Baker, Health GAP Northeastern U. School of Law, Program.
1 Bolar Provisions in Europe Robert Watson Chartered Patent Attorney European Patent Attorney AIPLA, February 2006.
FREE TRADE AGREEMENTS Prathibha Siva Lawyers Collective HIV/AIDS Unit, India East Africa Consultation, September 2010.
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
Overview of presentation
INTELECTUAL PROPERTY RIGHTS
Intellectual Property Protection and Access to Medicines
Patent law update.
Generic Medicines.
Speeding access to therapies
Suzanne M. Sensabaugh, MS, MBA
Research, Experimentation, & Clinical Trials
Intellectual Property Rights in Medicines Procurement
Presentation transcript:

Test data protection TRIPS requirements & TRIPS-plus provisions Carlos Correa

Test data Safety – Efficacy Empirical information obtained through the application of standard protocols Preclinical and clinical trials

Data exclusivity During the data exclusivity period, national drug authorities cannot use or rely on test data to register generic equivalents

As long as data exclusivity lasts… Generic manufacturers must => Repeat the clinical trials => Wait until the expiry of the data exclusivity period

TRIPS Article 39.3 Members, when requiring, as a condition of approving the marketing of pharmaceutical or of agricultural chemical products which utilize new chemical entities, the submission of undisclosed test or other data, the origination of which involves a considerable effort, shall protect such data against unfair commercial use. In addition, Members shall protect such data against disclosure, except where necessary to protect the public, or unless steps are taken to ensure that the data are protected against unfair commercial use.

PROTECTION OF UNDISCLOSED INFORMATION Article In the course of ensuring effective protection against unfair competition as provided in Article 10bis of the Paris Convention (1967), Members shall protect …data submitted to governments or governmental agencies in accordance with paragraph 3.

USA v Argentina: WTO settlement  -Argentina kept its system based on fair competition law  - Argentina committed itself to change its law if WTO established that exclusivity was required under TRIPS

Countries without data exclusivity for pharmaceuticals -Brasil - Filipinas - Ghana - India - Indonesia - Malaysia - Pakistan - Thailand - Uruguay

Patent Registration; market entry End patent term Data exclusivity Beyond patents Registration for new indication Data exclusivity

Colchicine : 3 years of data exclusivity -Widely available as a generic drug for gout pain in the USA since the 19th century: second-line treatment for gout -Tests with 185 patients, one week: shortened dosing regime : - Lawsuits to remove any other versions of colchicine from the market -Price increase by a factor of more than 50, from $0.09 per pill to $4.85 per pill.